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Abstract
Drug discovery in neuro- and psychopharmacology is lagging, and the most commonly mentioned
cause is the scarcity of drug targets. Using NextGen ‘Sequencing Based Single-Cell
Transcriptomics’ (SBSCT), several hundred different receptors and channels can be identified in
individual neurons, and the functional gene product can subsequently be validated. The use of
single-cell transcriptome data to reveal the entire receptor repertoire is crucial, as the copy
numbers of mRNAs encoding receptors are low and when cells are pooled, dilution of rare
mRNAs leads to loss of signal. These overlooked receptors on key neurons often mediate robust
effects that may be therapeutically useful. SBSCT also enables the identification of orphan
receptors and can provide strong evidence for receptor heterodimers. Here, we compare SBSCT to
other single-cell profiling methods. We argue that the unbiased nature of SBSCT makes it a
powerful tool for the identification of new drug targets.
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Single-cell profiling is important for drug discovery
A key to modern drug discovery is the availability of high quality, new drug targets. Some
therapeutic areas such as oncology and inflammation/immunity are rich in drug targets,
whereas psychiatry and neurology are, as of today, poor in good drug targets 1-3. The
identification of promising drug targets in neuropsychiatry is essential for further drug
development and will also help us to better understand underlying illnesses. During the past
thirty years, a confluence of techniques such as chemical neuroanatomy, lesion studies,
radioreceptor binding, Cre/lox deletion of identified cells, positron emission tomography
(PET) and functional magnetic resonance imaging (fMRI) have helped to identify key
neuronal circuits and individual neurons involved in regulating multiple physiologies such
as seizure threshold, mood, reward, and working memory (cf 4,5). The neurons of these
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circuits serve as important cellular targets for pharmacological interventions, and the cell-
surface receptors and ligand-gated ion channels of these neurons form the two most
important classes of drug targets that are accessible from the extracellular space. Thus, it
would be desirable to know whether there are receptors and ligand-gated channels (or
combinations thereof) that are selectively expressed by these neurons. It would also be
useful to know the relative ratios of their expression. It is our goal to highlight the
opportunities for target discovery and therapeutic development inherent in single-cell
analysis, which includes Nextgen sequencing and functional genomics (Figure 1).
Today we know the functional identity of only ~20-30 receptors and channels in most of the
important central neurons. For example, a literature study of the neurons implicated in the
hypoglutamatergic theory of schizophrenia 6-8 shows that the dopaminergic cells in the
ventral tegmental area (VTA), pyramidal cells in the cerebral cortex layers 3-5, and the
gabaergic interneurons in the cerebral cortex and VTA possess fewer than 30 known
receptors, and only two or three are exploited as drug targets. This is in contrast with what
would be possible to know, as suggested by multiple studies on single neurons over the past
10 years 1,9-13. These studies using (i) single-cell polymerase chain reaction (PCR), (ii)
chipping, and now (iii) single-cell sequencing have shown that neurons in the central
nervous system (CNS) can express mRNAs for several hundred receptors and that ~10-20%
of these are orphan receptors, as suggested by the analysis of G protein-coupled receptors
(GPCRs) identified in other CNS neurons 14. The advantages of studying a single cell over
dissected or microdissected (punched) or laser dissected groups of cells can be summarized
by showing that rare mRNAs are diluted when the contents of several cells are pooled, and
the dilution may lead to their concentration falling below the detection limits of the methods
used. Thus, the presence of rare mRNAs will be missed. This represents a serious scientific
and drug development opportunity loss, as GPCRs and ligand-gated ion channels are among
the most druggable targets. The copy number of both gene products and of mRNAs
encoding receptors and ligand-gated ion channels varies between 2 and a few hundred for
the mRNAs (cf. ref 5), and the number of GPCRs (as determined by labeling methods) is
~200-2000 per mammalian neuron.
The therapeutic effects exerted through these receptors are robust, and thus we would like to
know all the receptors through which such effects are attainable. However, neighboring cells
that are included in pooled cell populations usually do not have the same receptor repertoire;
they can vary to the extent that we find very different electrophysiological properties among
neighboring neurons. Therefore, for detecting the receptor mRNA and also in studying
functional receptors in neurons, the single-cell methods of molecular biology and of
electrophysiology have great advantages. Table 1 provides a comparison among the methods
presently available to identify expression of a receptor on a single cell. The functional
expression of a receptor on a single cell is best studied electrophysiologically if an agonist is
available for the receptor. The expression of the gene product (the receptor protein) can be
shown when antibodies properly labeled or labeled ligands to the receptor are available,
whereas the mRNA encoding a receptor can be identified with methods such as single-cell
PCR, in situ hybridization (ISH) and microarray, in addition to the sequencing-based single
cell transcriptomics (SBSCT) described in this paper.
For most methods, one utilizes knowledge from earlier physiological and pharmacological
studies for the analysis at hand. These a priori known data focus the search for a receptor or
a set of receptors. For example, if immunohistochemistry shows that, at synapses with the
neuron under study, there are nerve terminals containing the serotonin biosynthetic enzyme
tryptophan hydroxylase, or if retrograde tracing studies show that the neurons from the
dorsal raphe nucleus project to the area where the studied neuron is, then it is reasonable to
examine which subtypes of serotonin receptors are expressed by the neuron (as the dorsal
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raphe nucleus cells are known to release serotonin 16). No one, however, studies every
receptor antibody or uses a set of PCR primers that would detect mRNA encoding every
receptor in the genome. Thus, the studies are biased by previous a priori knowledge, and
this directs the experimental paradigm to what has already been studied.
In contrast, the ISH atlases that are constructed using as probes to all possible receptor
mRNAs present in the genome and study all areas of the brain irrespective of earlier
identification of the receptor or of the orphan receptors in that area 15, and SBSCT 14 are
unbiased by prior knowledge and thus may yield surprising findings. Here, we will discuss
how SBSCT has revealed the presence of adiponectin, insulin and insulin-like growth factor
1 (IGF1) receptors, on the warm sensitive neurons (WSNs) of the hypothalamus. As the
Table 1 shows, one pays a price in time and cost of the SBSCT as compared to single cell
PCR or microarray, but we believe that it is well compensated by the unexpected and rich
results obtained.
SBSCT compared with other methods of single-cell profiling
The advantages of single cell transcriptomics over pooled cells or tissue sample
transcriptomics have been discussed many times previously. The advantages of single cell
methodologies lie in their higher sensitivity, higher specificity and co-localization within the
same cell type of information leading to the discovery of which mRNAs are indeed
expressed in the same cell. This provides a basis for the study of whether the gene products
of multiple targets may directly associate through the formation of dimers or other
interactions. This in turn leads to a tighter coupling between molecular data and cellular
function as long as one has methods to study the single cell, which in neuroscience is the
standard of electrophysiology. The comparison of SBSCT with other single-cell
transcriptomics is important to elucidate what is required and what can be gained by use of
this method (Table 1).
Historically, the first single-cell transcriptomics analysis was performed on a single
cerebellar Purkinje cell, in which the mRNA was isolated using a glass capillary tube and
amplified using the linear aRNA amplification methodology 21. This was followed by an
analysis of individual rat hippocampal neurons 9,22 and striatal neurons 23-25. Data from
these papers was limited to an analysis of selected RNAs from these cells as whole
transcriptome analysis was not technologically feasible until microarray 26 and subsequent
NextGen sequencing analysis methods became available. Initially, single-cell PCR 27,28 was
used to characterize particular RNAs within the RNA compliment of single cells, and this
was followed by microarray analysis of the RNA populations 26. Since these early papers,
there have been many publications detailing single-cell transcriptomes using various
methods (cf 13).
The SBSCT method makes use of the development of less costly sequencing methods that
enable the mRNAs that are amplified by PCR or linear amplification, not probed by PCR
primers or by DNA arrays, to be identified in the most specific manner possible. The great
advantage of this method is that it is unbiased, (i.e., making no assumption regarding which
mRNAs may be present as one must do when selecting PCR primers or when spotting
probes on a DNA microarray). In SBSCT, one indiscriminately sequences all cDNAs of a
single cell, and thus one will discover, upon comparison with the genome, unexpected
mRNAs. Furthermore, SBSCT applies sequencing of whatever cDNAs are made by
amplification of the single cell mRNAs rather than hybridization with fixed probes as a
microarray. It therefore permits the identification of unexpected isoforms of both expected
and unexpected transcripts. Both of these types of findings are precluded by the planning of
the PCR and microarray experiment in the selection of targets, primers and probes. The
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unbiased sequencing of a single cell represents a major step forward in describing the
complete transcriptome of the cell.
All of these methods start with single cell RNA that is reverse transcribed. Although single-
cell PCR in principle can be carried out on the cDNA obtained, chipping or microarray
analysis and SBSCT require linear amplification of the cDNA given the small amount of
material collected. Amplification directed by the poly-A tails of mRNA introduces a 3’ end
bias that represents a significant drawback to microarray analysis as most probes cover the
coding region, and thus no hybridization will occur at many sites despite the RNA being
present. This loss of information is not seen with SBSCT because any sequence detected can
be mapped back to the genome without being selected in advance.
Microarray analysis is significantly faster and cheaper today than the NextGen sequencing
of the RNAs from a cell. However, the computational needs of SBSCT identification of the
mRNAs are completely dependent on finding the matching genomic sequences and require
resources that exceed those needed for microarrays. One of the biggest issues related to
sequencing analysis is the decision about what to do with experimentally obtained sequences
that have one or more mismatches, and how to use them to further investigate the presence
of their associated mRNAs. PCR or other methods may provide additional data regarding
the exact nature of these sequence variations, but so far we have discarded them, an
embarrassment of the riches as we already had 5000 identified mRNAs. This issue will be
abrogated as NextGen sequencing improves, permitting longer sequences with fewer errors
to be generated. In the meantime, questions about non-perfect sequences arise. For example:
is a mismatch closer to 5’ end worse than one closer to 3’ end, and how much inaccuracy is
caused by biology and how much by methodology?
The biggest issue in using transcriptomics data, whether generated from single cells or tissue
samples, is the determination of how the transcriptome relates to the proteome and which of
the identified mRNAs will be translated into functional gene products. In the study of
neurons, the mRNA-encoded receptor, ligand-gated channel, or voltage-gated channel can
be interrogated by single-cell electrophysiological methods (e.g. patch clamp) that can study
a single ion channel or show functional expression of several channels or receptors using the
whole cell configuration. We have applied the latest version of this single-cell transcriptome
approach, now complemented with sequencing based analysis of the linearly amplified
mRNAs from a single neuron, to the study of electrophysiologically identified WSNs from
the mouse. The WSNs are GABAergic neurons in the anterior hypothalamic preoptic area
(POA) that project to the raphe pallidus and dorsomedial hypothalamus 18. These neurons
show temperature sensitive changes in their spontaneous firing in the temperature range
between 33-41°C and are responsible for regulating and maintaining core temperature 19,20.
We have studied the WSNs in great detail because these cells have a decisive effect on a
macro, in vivo parameter, the core body temperature (CBT), that can be measured with a
simple thermometer 18-20. The effect of changes in the activity of a few WSNs can thus be
followed by robust changes in CBT, providing functional expression of an mRNA encoded
receptor or channel. In these neurons, we can study the effects of all agonists to receptors
whose mRNA we identified by SBSCT, and we have done so by measuring
electrophysiological changes such as firing activity, input resistance, and by measuring
changes in the CBT of whole animals upon microinjecting to the area where these neurons
are found. As our search through sequencing was unbiased, we have come upon receptors
that were not previously suggested to be expressed or to be functional in these neurons in the
literature. The most surprising of these examples is the insulin receptor that was discovered
through identifying its 3’UTR sequence. The mRNA was present in low copy numbers
(below 10), and yet application of insulin changes the firing rate of these neurons and
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microinjection of insulin causes large sustained hyperthermia. We identified 45 non-orphan
GPCRs. In functional tests, we could confirm the expression of functional receptors in 90%
of the cases (i.e., in the case of 32 peptides and 7 small molecules, Glu, GABA, Ach,
monoamines) despite large variations in the copy number of the mRNAs.
The experimental paradigm of SBSCT and the technical prerequisites
The neurons
Many important neurons in key circuits can today be recognized by morphological markers,
by being tagged with promoter-driven green fluorescent protein (GFP) expression in
transgenic animals 29, or by identification of their specific activity profile. Once individual,
active neurons are recognizable in tissue slice or in vivo, whole-cell patch clamp recordings
can be made from them. This mode of electrophysiological characterization also opens the
way for physically sampling the cell for the transcriptome studies. In several cases, such as
the fast firing cortical GABAergic neurons, electrophysiology is the best method of
identifying neurons of interest. As discussed above, we have focused on the WSNs 14, which
are located in the POA of the neuronal circuit that regulates adaptive thermogenesis and can
activate the brown adipose tissue upon changes in skin temperature or upon changes in CBT.
This neuronal circuit has been pieced together by lesion studies, retrograde tracing studies
and recording studies and is summarized by Nakamura and Morrison 18.
Single-cell cDNA library
The individual neuron cDNA library is prepared by reverse transcription of the RNA
population isolated from individual neurons, followed by repeated rounds of linear aRNA
nucleic acid amplification (23-25) and conversion of the amplified RNA into a cDNA library.
The resulting cDNA library has sufficient quantities of amplified material from a single
neuron to permit sequencing of these cDNAs, microarray analysis, and the PCR of selected
targets. As used in these studies, the linear amplification biases the amplified products
towards the 3’ end, and although many microarray platforms will not have probes that can
hybridize with the 3’-end biased RNA, the unbiased sequencing (i.e., not requiring for
knowledge of hybridizable sequences) will clearly identify the cDNA and the gene from
which it originates. When identifying which mRNAs are present in the individual neurons,
we have characterized them first by electrophysiology and then by SBSCT. For the SBSCT,
30 million individual sequences (also called reads) can be generated for an individual cell
with ~70% of the reads mapping back to known genes. Using stringent genome matching
parameters permitting only 100% matching sequences for the 45 base sequences generated,
we have identified ~5000 cDNAs in a single neuron using Illumina sequencing14. Permitting
one or even two mismatches would increase this number dramatically.
An analysis of published sequencing data for single non-neuronal cells reveals a similar
reported distribution of functional classes of mRNAs for detectable transcripts (Figure 2).
Using a single mouse oocyte 11 and single embryonic stem cells 30, Tang et. al. describe
single-cell gene expression profiles generated by whole transcriptome amplification
followed by Applied Biosystems’ next generation SOLiD sequencing. Evaluating this
dataset for the presence of transcripts described as receptors, ion channels or enzymes
having one or more read count gave a distribution of 5-6% of transcripts encoding receptors,
1% encoding ion channels and 23% encoding enzymes, respectively. Although
approximately the same percentage of transcripts encodes receptors in each cell type,
neurons, in particular, may produce more copies of each of these receptor types to
accommodate signaling across their extensive membrane surface area 11,14.
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Functional validation of transcriptome data
The presence of receptor mRNAs in a cell does not automatically mean that the receptors are
translated or functional, but rather shows the potential of that cell to respond. Indeed it is
possible that mRNAs are translationally silent until a proper stimulus permits their
translation, insertion into the membrane and function. Validation of the function of the
receptor within a cell is required to understand the role of the receptor in mediating cellular
physiology. We have used “tried and true” pharmacological and physiological tools as well
as genetically engineered animal models as a means of functionally validating receptors
highlighted by SBSCT. Among the several hundred receptor cDNAs identified in the WSNs
were those encoding pyrogen receptors, as expected, because the earliest iontophoresis
studies showed these cells to respond to pyrogens such as interleukin-1 (IL-1) and tumor
necrosis factor alpha (TNFα) 30, as well as several glutamate and GABA receptor
subtypes 31. The effect of agonists on these receptors has been examined on WSNs in slices
electrophysiologically and/or in vivo with radiotelemetry measuring CBT after
microinjection of the agonists into POA. The neuronal circuit in which WSN is the principal
neuron controls the CBT, the maintenance of which accounts for 30% or more of the energy
expenditure of homeotherms like humans. The knowledge of the receptors through which
CBT and energy metabolism can be affected chronically is of pharmacological importance
in weight control and metabolic disease. We have identified several hundred mRNAs that
encode cell-surface receptors in WSNs, a cell type that after over 30 years of studies has
revealed only ~20 receptors (cf 19). These SBSCT data have enabled us to determine the
receptor subtype mediating effects of signaling substances known earlier to be able to effect
CBT. For example, it was known that intracerebroventricular (icv) injection of bombesin
caused hypothermia 32, and our finding of the bombesin receptor 3 (BSR3) in the WSN
suggests that some of the effects of icv bombesin 32 are exerted in the anterior hypothalamus
on these particular cells through the BSR3.
Receptors for non-synaptic signals
The unbiased nature of SBSCT does not require that the afferents to a neuron are known a
priori. This permits the discovery of hormone receptors, chemokine and cytokine receptors
and receptors for some neuropeptides that do not reach the neuron through synaptic contacts
with an afferent neuron but rather by diffusion in a volume transmission 4. The hormone
receptors in the WSNs for insulin 33, IGF1 34 adiponectin 14, and the chemokine receptor for
CCL4 35 were thus found by SBSCT without any previous suggestion, anatomical or
otherwise, that these neurons express receptors for these non-neuronal, non-synaptic signals.
Once SBSCT identified these receptor transcripts, the gene product and their functional
effect on the WSN activity and on CBT was demonstrated 33-35. The sequencing-based
finding of the expression of the insulin receptor mRNA 33 permitted us to demonstrate that
insulin in the POA mediates hyperthermia through activation of the brown adipose tissue.
The discovery of adiponectin1 and 2 receptors in the WSN allowed us to demonstrate that
these receptors are involved in insulin-mediated hyperthermia 14, and the receptors for the
chemokine CCL4 in the WSN demonstrated that this chemokine acts as a hyperthermic
agent when applied to the POA 35.
We found IGF1 receptor transcripts in several cells that expressed insulin receptor (IR)
transcripts 34. Thus, it is likely that some IR-IGF1R heterodimers exist in these WSN cells,
something that has been proposed based on heterologous expression and the examination of
pooled cells 36, but now that the transcripts were found in a single cell, the formation of the
heterodimer is more likely. The identification of the heterodimers of receptors like IR-
IGF1R are of great pharmacological significance because their behavior and their ligand
selectivity may be different from that of receptor homodimers, opening up pharmacological
specificity of action for heterodimeric receptor-selective ligands 37,38.
Bartfai et al. Page 6
Trends Pharmacol Sci. Author manuscript; available in PMC 2013 January 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Orphan receptors
Like the presence of the non-synaptic receptors, the presence of orphan receptors is not
suggested by afferent neurons, and thus detection methods such as the ISH atlas, PCR,
microarray and SBSCT can assist in their identification in a neuron. Using SBSCT, we have
identified 21 orphan receptors (GPCRs) in the WSN 14, providing novel drug targets that are
being pursued presently by medicinal chemists. Some of the GPCRs were already null
mutated, and the phenotypic analysis of the mice shows interesting energy metabolism
related phenotypes (e.g. GPR119 39). In other cases (e.g. GPR 3, 17, 21, 40, 83, 85) the
study of the knockout strain, siRNA mediated knock down, and/or exogenous ligands are
being pursued to determine their effects on WSN activity and energy metabolism 40,41.
Microarray analysis of the same cDNA library of the single cell that was sequenced did not
give any hybridization signal for the prolactin (PRL) receptor mRNA, despite the presence
of three probes on the array. This was because the probes were from the protein coding
region of the mRNA, whereas the single cell probe was highly enriched for the 3’-
untranslated region (UTR) of the mRNA. Although a 3’-end bias to the probe is expected
when using the poly-A region of the RNA to direct probe generation, the reason for the very
strong 3’-end bias for the PRL receptor is not clear. It may result from a strong RNA
secondary structure that blocks movement of the probe generating enzyme from moving
beyond this region 42 As the 3’-UTR was not represented on the microarray, no
hybridization would occur and the RNA would be classified as absent from the sample.
However, the unbiased sequencing (i.e., no reliance upon selection of hybridization probes)
identified the PRL receptor and has led to establishing its role in regulating CBT, thus
highlighting the increased sensitivity and the lack of bias as compared to standard
microarray analysis. An intriguing aspect of single-cell molecular biology is not only the
detection of the presence or absence of a particular mRNA but also the information obtained
regarding the relative and absolute abundances of these mRNAs.
Discovery of orphan receptors is accelerated by SBSCT
The localization of orphan receptor mRNAs to a given neuron has been earlier achieved by a
set of methods that each has biases and limitations overcome by SBSCT: in ISH, PCR
analysis, and microarray. ISH studies are unbiased but often have low resolution for
transcripts under scrutiny. Of the 21 orphan receptors we identified in the WSNs (14), we
could have found in the Allen Barin atlas only 60%. Furthermore, we would not have known
whether these are expressed in warm-sensitive or insensitive cells as there is no
morphological marker for warm sensitivity of a neuron, with which we could have
established co-localisation. The PCR analysis of the cDNA prepared from selected neurons
is biased by the decision that a particular orphan receptor should be sought; only a few
dozen PCR primer pairs are usually tested on the same neuronal transcriptome. The
microarray analysis of the single neuron transcriptome is unbiased by earlier information
about which afferents this neuron receives, but it is limited by which orphan receptor probes
are synthesized and spotted on the array. The sequencing of the transcriptome does not
anticipate anything about which mRNAs may be found in the cell under study, and thus it is
not biased regarding which sequences will be found for orphan receptor mRNAs, coding or
non-coding regions, etc. The use of sequencing as part of SBSCT makes this paradigm
presently the most unbiased method of finding an orphan receptor mRNA in an identified
neuron as described in this paper.
Once the mRNA or the gene product of an orphan receptor is identified in a neuron,
functional validation of the gene product orphan receptor can be accomplished using
exogenous ligands. These exogenous ligands are identified by high throughput screens
(HTS) using a heterologously expressed orphan receptor along with ligand libraries to test
Bartfai et al. Page 7
Trends Pharmacol Sci. Author manuscript; available in PMC 2013 January 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
whether the orphan receptor protein is functionally expressed. Finding functional orphan
receptors on important neurons is a major bonus for drug developers who can generate
selective potent ligands that may act as therapeutic agents without knowledge of the
endogenous ligand of the receptor – i.e., prior to its deorphanisation. This is reminiscent of
the successful therapeutic use of opiates for several thousand years prior to the identification
of the endogenous opioid receptor ligands enkephalins and endorphins. When a safe and
efficacious dose is known, therapeutic use starts independent of whether all the receptors the
substance binds to are known.
Concluding remarks
Our studies on the WSNs in the mouse hypothalamus 14,33-35 and on pyramidal cells in rat
hippocampus 43 using SBSCT have shown that most CNS neurons express mRNAs
encoding 200-500 or more receptors, albeit in highly varying copy number per cell. The
SBSCT and validation results show that the neuronal transcriptome (the RNA complement
of a cell) and proteome (the protein complement of a cell) are usually in good concordance
with each other, and thus the 200-500 receptor proteins are likely present as membrane
proteins and could be useful as putative drug targets. The sequencing of individual cell
cDNA libraries permits the identification of receptor and ion channel expression profiles for
a specific neuron whose electrophysiological profile has been recorded prior to cDNA
library preparation. The changes in the electrophysiological activity profile can be used to
check the importance of the identified receptors and ion channels by measuring the direction
(excitatory or inhibitory, depolarising or hyperpolarising, activating firing or silencing) and
robustness of the effect on the neuronal activity upon application of agonists. Sequencing of
the cDNA library of these cells may reveal pharmacologically important isoforms of a
receptor present in the given neuron, and also show when receptors that can form
heterodimers are expressed in the same cell, making it possible that such heterodimers are
indeed present.
SBSCT may increase by ten times the number of identified receptors on key neurons within
defined neural circuits that contribute to specific behaviors or disorders. Having this
information at hand may indeed reveal several dozen receptors that are relatively selectively
expressed on a particular neuron type and thus could serve as useful drug targets in affecting
the activity of these particular neurons and neuronal circuits. Identifying ligands that act on
novel drug targets or selectively-expressed drug targets always provides hope of novel
therapeutic effect. Furthermore, combination therapies are used extensively in treatment of
pain, psychiatric disorders, and epilepsies but represent difficult clinical trial challenges. If
there is clear molecular evidence that two receptors are expressed on a key neuron, then
functional studies using agonists to both receptors can determine whether these receptors
mediate additive or even synergistic effects. If this is the case, then there would be a cellular
and molecular rational for testing ligands to these receptors in combination or even testing
novel ligands that are bifunctional agonists at both receptors44.
Clearly the identification of drug targets is but one of the first steps of a drug discovery
program that often takes 10-12 years. Nevertheless, in neuropsychiatry the lack of drug
targets is often identified as the bottle neck 3,45-47, and we believe that use of SBSCT on
neurons that are well identified components of important neuronal networks is today
feasible, affordable and will provide more scientific, actionable information. Access to many
more putative targets eases the pressure to work on receptors for which poor leads were
found or those known to be expressed on tissues outside of the circuit of interest (which
suggests a risk of side effects of a future ligand). SBSCT does not address problems of drug
delivery or other issues, but it should provide many more putative targets for potential
clinical validation.
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We have focused on illustrating the benefit that knowledge of cell-surface receptors and
channels provides with regard to anticipating cellular pharmacological responsiveness.
However, we do not imply that these are the only classes of drug targets that SBSCT
reveals; the 5,000 identified mRNAs per individual cell code for over 4,000 potential
intracellular targets for drugs. Although these other targets may be useful, we have
highlighted the cell-surface receptors as these are a highly druggable class of proteins used
extensively by the pharmaceutical industry and drug developers. We wanted to emphasize
that the use of single cells and sequencing in combination is particularly advantageous in
identifying receptor encoding mRNAs that are rare, low copy number transcripts in need of
avoiding dilution through pooling cells and in need of sequencing rather than microarray
detection to pick up isoforms. The presence of so many more than the currently identified
and pharmacologically targeted receptors on each cell and the presence of so many
unexpected (nonsynaptic, non-neuronal signal recognizing) receptor encoding mRNAs calls
attention to these receptors as putative drug targets beyond the traditional synaptic
pharmacology. The molecular detail SBSCT provides for CNS neurons heralds the need for
more dynamic functional genomics analysis of such datasets to be used in the physiological
and pharmacological understanding of the actions of these neurons. The iterative use of
single gene knockouts to investigate the function of single receptors is informative but time
consuming and limited in scope. It is our belief that the SBSCT analysis of key cells will, by
multiplying the number of known putative drug targets on these cells, give new impetus to
drug discovery that suffers from a shortage of drug targets in areas such as neurology,
psychiatry and pain therapy.
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Figure 1. Sequencing based single cell transcriptomics (SBSCT) for drug target identification
The workflow illustrated in this schematic details how SBSCT can be used to identify drug
targets. First, a neural circuit underlying pathophysiological behavior is identified. Next, key
neurons within the circuit are identified through electrophysiological studies (ElPhys) or
through specific tags, such as with GAD-GFP (glutamic acid decarboxylase-green
fluorescent protein). Next, whole cell patch clamp is used to electrophysiologically
characterize the cell and the patch pipette is then used to collect the RNA from an individual
neuron. This RNA is then amplified into quantities that permit sequencing, microarray and
PCR to be used to assess the presence and abundance of mRNAs from the cell. For SBSCT
in particular, all mRNAs of a single cell are sequenced indiscriminately. Finally, the
function of the mRNA encoded receptor, ligand-gated channel, or voltage-gated channel can
be interrogated by single cell ElPhys methods that, like patch clamp, can study a single ion
channel being expressed from an mRNA or show functional expression of several channels
or receptors using the whole cell configuration. Other methods to validate functionality can
include selective phenotyping (null or over-expression of a given receptor or channel), small
interfering RNA (siRNA)-mediated knockdown, and/or microinjection of the related ligand.
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Figure 2. Gene onotology (GO) categories for mRNAs identified in individual cells
Comparison of the expression of mRNAs in GO categories from various mouse cells shows
that there are large numbers of receptors in each cell type. In this example, a single
hypothalamic POA neuron is compared with a single oocyte and a single blastomere from a
four-cell stage embryo (MF1 strain). Although the total number of mRNAs detected in the
hypothalamic neuron is 6120, the oocyte and blastomere have a larger number of detectable
mRNAs (14,215 and 15,595 respectively), each cell type has a large proportion of expressed
mRNAs annotated as receptors. The percentage of total RNA devoted to receptors was
highest in the hypothalamic neuron at 8%, whereas the other cell types range from 5% to
6%. Although GPCRs have been shown to homodimerize and heterodimerize under certain
conditions, channels are known to heterodimerize extensively. Therefore, the presence of
~90 mRNAs that encode channel subunit proteins suggests a large repertoire of heteromeric
channels.
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